Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
By Phase
10 drugs in development
By Therapeutic Area
top 4
R&D Momentum
91/100
Pipeline Velocity
67/100
Trial Completion Rate
58/100
Pipeline Concentration
33/100
Pipeline Freshness
61/100
Strategic Signals
Activity
Last 14 days
An Open-Label, Single-Center, Investigator Initiated Phase 1B Trial of E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas
68Ga(Gallium)-DOTATATE Positron Emission Tomography (PET)/MRI in the Diagnosis and Management of Somatostatin Receptor Positive Central Nervous System CNS Tumors.
Optimizing Pain Treatment in Children On Mechanical Ventilation
Brain [18F]-FES PET/CT in the Diagnosis, Treatment Planning and Response Assessment of Brain Metastases in Patients With Estrogen-Receptor Positive Breast Cancer
Feasibility and Acceptability of Pain Reprocessing Therapy in Racially/ Ethnically Diverse Adults With Chronic Back Pain
Accelerated Radiation Therapy (ART) To The Breast And Nodal Stations After Neo-Adjuvant Systemic Therapy And Surgery: A Feasibility Study
Mechanistic Clinical Trial of Beta-Blocker Administration For Reactivating Cardiomyocyte Division In Tetralogy of Fallot
A Phase I, Open-Label, Dose-Finding Study of TVB-2640 Administered in Combination With Enzalutamide (Xtandi) in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
A Phase Ib, Dose-Escalation Study of Augmented Lymphodepletion and CAR T-cell Priming With Low-dose Total Body Irradiation in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphomas and Multiple Myeloma Receiving Treatment With Commercial CD19 or BCMA-directed CAR T-cell Therapies
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Pipeline
Regulatory
Fludeoxyglucose F18 — FLUDEOXYGLUCOSE F18
Application NDA021870
Fludeoxyglucose F18 — FLUDEOXYGLUCOSE F18
Application NDA021870
Fludeoxyglucose F18 — FLUDEOXYGLUCOSE F18
Application NDA021870
Fludeoxyglucose F18 — FLUDEOXYGLUCOSE F18
Application NDA021870
Fludeoxyglucose F18 — FLUDEOXYGLUCOSE F18
Application ANDA203902
Fludeoxyglucose F18 — FLUDEOXYGLUCOSE F18
Application ANDA203246
Fludeoxyglucose F18 — FLUDEOXYGLUCOSE F18
Application ANDA203778
Fludeoxyglucose F18 — FLUDEOXYGLUCOSE F18
Application ANDA204472
Fludeoxyglucose F18 — FLUDEOXYGLUCOSE F18
Application NDA021870
Fludeoxyglucose F18 — FLUDEOXYGLUCOSE F18
Application ANDA204531
Fludeoxyglucose F18 — FLUDEOXYGLUCOSE F18
Application NDA021870
Fludeoxyglucose F18 — FLUDEOXYGLUCOSE F18
Application ANDA203837
Fludeoxyglucose F18 — FLUDEOXYGLUCOSE F18
Application ANDA203904
Fludeoxyglucose F18 — FLUDEOXYGLUCOSE F18
Application NDA021870
Fludeoxyglucose F18 — FLUDEOXYGLUCOSE F18
Application ANDA203942
Fludeoxyglucose F18 — FLUDEOXYGLUCOSE F18
Application NDA021870
Fludeoxyglucose F18 — FLUDEOXYGLUCOSE F18
Application ANDA203778
Fludeoxyglucose F18 — FLUDEOXYGLUCOSE F18
Application ANDA203246
Fludeoxyglucose F18 — FLUDEOXYGLUCOSE F18
Application ANDA203902
Fludeoxyglucose F18 — FLUDEOXYGLUCOSE F18
Application NDA021870
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)